Breaking the FDA monopoly: with dual-tracking, patients can have early access to potential miracle drugs while the FDA maintains its testing regimen.(Health & Medicine): An article from: Regulation

This digital document is an article from Regulation, published by Cato Institute on June 22, 2004. The length of the article is 1828 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Breaking the FDA monopoly: with dual-tracking, patients can have early access to potential miracle drugs while the FDA maintains its testing regimen.(Health & Medicine)
Author: Bartley J. Madden
Publication:Regulation (Refereed)
Date: June 22, 2004
Publisher: Cato Institute
Volume: 27 Issue: 2 Page: 64(3)

Distributed by Thomson Gale